Antipsychotic Drugs: Technologies and Global Markets Report 2018 - Estimates & Projections 2017-2023 - ResearchAndMarkets.com

October 5, 2018

DUBLIN--(BUSINESS WIRE)--Oct 5, 2018--The “Antipsychotic Drugs: Technologies and Global Markets” report has been added to ResearchAndMarkets.com’s offering.

This report provides a detailed description of the market for antipsychotic drugs. The report highlights the current and future market potential of antipsychotic drugs and provides a detailed analysis of the competitive environment, regulatory scenario, technological advancements, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market shares for key market players. The report segments the market for antipsychotic drugs based on the mechanism of action, disease indication and geography.

Based on the mechanism of action, the market is segmented into D2 antagonists, D2/5HT2A antagonists and D2 partial agonists. The market size includes both branded and generic drugs. Based on disease indication, the market is segmented into schizophrenia, bipolar disorder, major depressive disorder (MDD), and other diseases including anxiety, autism and dementia.

By geography, the market has been segmented into the North America, Europe, Asia-Pacific, South America, and Middle East and Africa regions. The North America region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., France, Italy, Spain and the rest of Europe. Asia-Pacific includes China, India, Japan and the rest of Asia-Pacific. For market estimates, data has been provided for 2017 as the base year, with forecasts for 2018 through 2023.

The Report Includes:

Analyses of global market trends, with data from 2017, estimates for 2018 and projections of CAGRs through 2023 Country specific data and analysis for United States, Canada, Mexico, UK, France, Germany, Italy, Spain, China, India and Japan Definition, history and types of antipsychotic drugs An understanding on receptor target of antipsychotic drugs, including dopamine, serotonin, glutamate, tachykinin and glucocorticoid Coverage of various psychotic diseases and their indication including schizophrenia, bipolar disorder, major depressive disorder (MDD), anxiety, autism and dementia Comprehensive company profiles of key players in the market, including Alexza Pharmaceuticals, Dr. Reddy’s Laboratories, Ltd., Eli Lilly and Co., Johnson & Johnson, Teva Pharmaceutical Industries, Ltd., and Zydus Pharmaceuticals (USA), Inc.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary And Highlights

Chapter 3 Market And Technology Background

Chapter 4 Market Dynamics

Chapter 5 Market Breakdown By Mechanism Of Action

Chapter 6 Market Breakdown By Disease Indication

Chapter 7 Market Breakdown By Region

Chapter 8 Regulatory Scenario

Chapter 9 Patent Analysis

Chapter 10 Pipeline Analysis

Chapter 11 Competitive Landscape

Chapter 12 Company Profiles

Acadia Pharmaceuticals, Inc. Alembic Pharmaceuticals, Ltd. Alexza Pharmaceuticals Alkermes Plc Allergan Plc Apotex, Inc. Astrazeneca Plc Aurobindo Pharma Dr. Reddy’s Laboratories Ltd. Eli Lilly and Co Gedeon Richter Plc H. Lundbeck A/S Johnson & Johnson Lannett Co., Inc. Lupin, Ltd. Mayne Pharma, Inc. Mylan Nv Otsuka Holdings Co., Ltd. Sumitomo Dainippon Pharma Co., Ltd. Sun Pharmaceutical Industries Limited (Sun Pharma) Teva Pharmaceutical Industries, Ltd Torrent Pharmaceuticals, Ltd. Vanda Pharmaceuticals, Inc Wockhardt Zydus Pharmaceuticals (USA), Inc.

For more information about this report visit https://www.researchandmarkets.com/research/vtb55w/antipsychotic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181005005198/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Schizophrenia Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/05/2018 06:50 AM/DISC: 10/05/2018 06:50 AM


Update hourly